Learn Why Digirad Corp Purchased Aviragen Therapeutics, Inc Stake?

February 14, 2018 - By Ivan Hodges

 Learn Why Digirad Corp Purchased Aviragen Therapeutics, Inc Stake?

The New Digirad Corp Holding in Aviragen Therapeutics, Inc

Digirad Corp reported SC 13D/A form with the SEC for Aviragen Therapeutics, Inc. Access it here: 000092189518000563. As reported by Digirad Corp, the filler owns 8.3% or 3,195,106 shares of the Health Care–company.

Aviragen Therapeutics, Inc stake is new for [reportingPerson]. Date of activity: February 9, 2018. This shows Digirad Corp’s positive view for Aviragen Therapeutics, Inc.

Aviragen Therapeutics, Inc Institutional Sentiment

Filings show 52 investors own Aviragen Therapeutics, Inc. The ownership in Q3 2015 is high, at Infinity of the outstanding shares. This is increased by 4859143. 17292384 were owned by these investors. 5 funds opened new Aviragen Therapeutics, Inc stakes, 14 increased positions. There were 6 that closed positions and 13 reduced them.

Jw Asset Management Llc is an investor bullish on Aviragen Therapeutics, Inc, owning 8611 shares as of Q3 2015 for 0.01% of its portfolio. Senzar Asset Management Llc owns 1736400 shares or less than 0.01% of its portfolio. NY Towerview Llc have 0.17% of its portfolio for 160000 shares. Further, Bvf Inc reported stake worth 0.14% of its portfolio. The NY Krensavage Asset Management Llc owns 2570577 shares. Aviragen Therapeutics, Inc is 1.84% of its portfolio.

Business Profile

Aviragen Therapeutics, Inc., formerly Biota Pharmaceuticals, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.

SEC Form 13D.

It closed at $1.55 lastly. It is down 0.00% since February 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) Ratings Coverage

Among 2 analysts covering Biota Pharma (NASDAQ:BOTA), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Biota Pharma had 2 analyst reports since December 22, 2015 according to SRatingsIntel. The stock has “Outperform” rating by FBR Capital on Tuesday, December 22. HSBC initiated the shares of BOTA in report on Wednesday, January 27 with “Buy” rating.

More notable recent Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) news were published by: Businesswire.com which released: “Vaxart Issues Statement Regarding Proposed Merger With Aviragen” on February 01, 2018, also Streetinsider.com with their article: “Form 425 Aviragen Therapeutics, Filed by: Aviragen Therapeutics, Inc.” published on February 09, 2018, Streetinsider.com published: “Aviragen Therapeutics (AVIR) Says ISS Report Contains Numerous Factual Errors” on January 26, 2018. More interesting news about Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) were released by: Globenewswire.com and their article: “Aviragen Adjourns Special Meeting of Stockholders Until February 9, 2018” published on February 06, 2018 as well as Streetinsider.com‘s news article titled: “Aviragen Therapeutics (AVIR), Vaxart Amend Terms of Merger Agreement to …” with publication date: February 07, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.